NASDAQ · IMMP
Healthcare · Biotechnology
$0.37
Down-$0.04 (-11.30%)
Updated Sep 14, 2026, 5:20 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
IMMP does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning IMMP.
IMMP research
Company profile and research snapshot.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 30, 2026 | BELL POTTER SECURITIES | Hold | — |
| Mar 2, 2026 | JEFFERIES | Buy | — |
| Mar 1, 2026 | JEFFERIES | Buy | — |
| Jan 22, 2026 | JEFFERIES | Buy | — |
| Jan 21, 2026 | JEFFERIES | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 13, 2026
Key Results from INSIGHT-003 – Data Cutoff – 27 March 2026Approximately 92% of patients enrolled in INSIGHT-003 had no or low PD-L1 expression (Tumour Proportion Score: TPS <50%), representing a population with
Benzinga · Mar 6, 2026
Benzinga · Feb 23, 2026
Citizens analyst Reni J. Benjamin initiates coverage on Immutep (NASDAQ:IMMP) with a Market Outperform rating and announces Price Target of $10.
Benzinga · Feb 17, 2026
Citizens analyst Reni J. Benjamin initiates coverage on Immutep (NASDAQ:IMMP) with a Market Outperform rating and announces Price Target of $6.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IMMP.
No results
No recent SID articles mention IMMP.
